Poolbeg Pharma PLC (AIM: POLB) is stepping up partnering discussions with multiple pharma groups as it approaches a series of near-term clinical catalysts that could unlock a deal.
Poolbeg Pharma CEO speaks on BioHub podcast in London
In this episode of The BioHub Podcast, Max sits down in person in London with Jeremy Skillington, CEO of Poolbeg Pharma.
Why 2026 could be a defining year for Poolbeg Pharma
Poolbeg Pharma (AIM: POLB) enters 2026 at a point where several years of methodical clinical and strategic groundwork are beginning to converge. After a deliberately measured 2025 focused on trial
Poolbeg Pharma receives UK clearance to begin cancer immunotherapy trial
Poolbeg Pharma plc (AIM: POLB) has received Clinical Trial Authorisation (CTA) from the Medicines and Healthcare products Regulatory Agency for its POLB 001 TOPICAL trial, marking a key regulatory milestone
Why 2026 could be a defining year for Poolbeg Pharma
Poolbeg Pharma (AIM: POLB) enters 2026 at a point where several years of methodical clinical and strategic groundwork are beginning to converge. After a deliberately measured 2025 focused on trial
European Green Transition: Wind Energy Expansion & Pipeline Opportunities
StockBox spoke to Jack Kelly (CFO) and Dave Broadbank (MD, Wind Energy Services) of European Green Transition, where they discussed strong progress in the company’s wind energy services division following
European Green Transition plc (AIM: EGT) Q1 2026 Operational Update
European Green Transition plc (AIM: EGT), a company operating in the critical infrastructure sector, provides an operational update on its Wind Energy Services business for the three months ended 31
Roaring Waters Capital builds new 9.3% stake in European Green Transition
Roaring Waters Capital, based in Dublin, has disclosed a new major holding in European Green Transition plc (AIM: EGT) following an acquisition of voting rights on 31 March 2026.
Poolbeg Pharma (AIM: POLB) Significant milestone for Poolbeg’s IP portfolio
Grant of first POLB 001 cancer immunotherapy-induced CRS patent Significant milestone for Poolbeg’s global intellectual property portfolio
European Green Transition plc (AIM: EGT) Result of General Meeting
European Green Transition plc (AIM: EGT), a company focused on acquiring, integrating and optimising revenue-generating and profitable services businesses in the critical infrastructure sector, announces that, further to its circular
European Green Transition plc (AIM: EGT) UK proposals to increase onshore wind capacity
UK government proposals to increase onshore wind capacity
Poolbeg Pharma (AIM: POLB) Appointment of Dr Adrian Kilcoyne to SAB
Appointment of Dr Adrian Kilcoyne to Scientific Advisory Board